Gilead Sciences, Inc.
NEWS
As the coronavirus outbreak that causes COVID-19 escalates, biopharma companies and government agents are working quickly to develop and test a vaccine, although most estimates are it will take 12 to 18 months before it could get to market.
“This agreement builds on Gilead’s presence in immuno-oncology and adds significant potential to our clinical pipeline,” said Daniel O’Day, Gilead’s chairman and chief executive officer.
The month of February ended with a flurry of clinical trial announcements. Here’s a look.
Shares of Forty Seven Inc. were up in premarket trading on rumors that Gilead Sciences has approached the company about a potential partnership or acquisition.
The randomized, open-label, multicenter studies will enroll about 1,000 patients mostly in Asia, as well as in countries that have had high numbers of diagnosed cases. The trials are planned to start in March.
The most recent BioSpace Ideal Employer Report revealed the impact of team dynamics on employees within life sciences organizations.
The company indicated then that it still believes all four HHS PrEP patents are invalid and should not have been granted.
Biopharma and life sciences companies strengthen their leadership teams and board with this week’s Movers & Shakers.
The trial’s goal is to test more than 700 patients infected with the coronavirus, but at this point, there have been fewer than 200 people recruited.
JOBS
IN THE PRESS